Additional file 2 of Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study

Additional file 2: Table S1.Baseline characteristics by participant site. Table S2.Multivariate analyses of recurrence-free survival in total population (Cox model). Table S3.Multivariate analyses of overall survival in total population (Cox model). Table S4.Interaction between preoperative CEA and CA19-9 with risk of outcomes. Table S5.Multivariate analyses of recurrence-free survival in colorectal cancer subgroup with CEA < 5 ng/ml (Cox model). Table S6.Multivariate analyses of recurrence-free survival in colorectal cancer subgroup with CEA ≥ 5 ng/ml (Cox model). Table S7. Multivariate analyses of overall survival in colorectal cancer subgroup with CEA < 5 ng/ml (Cox model). Table S8.Multivariate analyses of overall survival in colorectal cancer subgroup with CEA ≥ 5 ng/ml (Cox model). Table S9.A frailty model analysis of preoperative CA19-9 (cutoff: 37 U/ml) on colorectal cancer outcomes in total population. TableS10.Cox proportional hazard regression analysis of preoperative CA19-9 (cutoff:74 U/ml) on colorectal cancer outcomes in total population. Table S11.Relationship between preoperative CA19-9 and benefit from adjuvant chemotherapyin patients with stage II colorectal cancer

Additional file 1 of Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study

Additional file 1: FigureS1. Association between preoperative CA19-9 status and overall survival. (a) overall population. (b) patients with normal preoperative CEA. (c) patientswith elevated preoperative CEA. Solid yellow lines are unadjustedhazard ratios, with dashed yellow lines showing 95% confidence intervalsderived from restricted cubic spline regressions. Reference lines for noassociation are indicated by the solid bold lines at a hazard ratio (HR) of 1.0. Dashed blue curves show the fraction of the population with different levels of preoperative CA19-9. Arrows indicate the concentration of preoperative CA19-9 with HR of 1.0. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; E, number of events; HR, hazard ratio; N, number of patients. FigureS2. Kaplan‐Meier curves for overall survival according to the preoperative CA19-9 group. (a) overall population. (b) patients with normal preoperative CEA. (c) patientswith elevated preoperative CEA. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen. FigureS3. Kaplan‐Meier curves according to the joint group of preoperative CEA and CA19-9 in colorectal cancer patients. (a) recurrence-free survival. (b) overall survival. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; OS, overall survival; RFS, recurrence-free survival. FigureS4. Forest plot for recurrence-free survival of preoperative CA 19-9 groups stratified by clinicopathological features based on the Cox models. P values for interaction were calculated using Cox regression model. HR and 95%CIs were given and visually represented by the squares and error bars. CA 19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio. FigureS5. Forest plot for performance overallsurvival of preoperative CA19-9 groups stratified by clinicopathological features based on the Cox models. P values for interaction were calculated using Cox regression model. HR and 95%CIs were given and visually represented by the squares and error bars. CA19-9, carbohydrate antigen 19-9; CEA, carcinoembryonic antigen; CI, confidenceinterval; HR, hazard ratio. FigureS6. Kaplan‐Meier curves according to the joint group of preoperative CEA and CA19-9 in patients with stage II colorectal cancer. (a) recurrence-free survival.(b) overall survival. CA 19-9, carbohydrate antigen 19-9;CEA, carcinoembryonic antigen; OS, overall survival; RFS, recurrence-freesurvival